Orthocell's Remplir sales in the U.S. hit a record high in October
Orthocell reported 92 Remplir units sold in the U.S. in October, worth AU$279K and 84% above its Q1 FY27 monthly average, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Orthocell Limited said it sold 92 units of Remplir in the U.S. in October, generating AU$279K in revenue. TradingView, citing a press release distributed by PR Newswire, reported the figures. The October volume was 84% higher than the Q1 FY27 monthly average of 50 units.
The company attributes the growth to rising surgeon adoption, repeat use, activity from its distributors and broader access across hospitals. October was the strongest month since the product launched in the U.S.
why it matters
For investors, this is the first clear step-up in U.S. usage of the device after the groundwork phase, though the company is small and its market impact is limited. For it to become a bigger catalyst, sustained growth over several months and new hospital approvals or guidance updates would be needed.
tags
instruments
sources
- Orthocell Limited (OCC) Posts Record U.S. Remplir Sales in October — TradingView, 2 November 2026 at 00:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗